Hantavirus Mortality Rate: Why It Ranges from 1% to 50% (And Which Number Matters)
When journalism talks about hantavirus, the mortality number cited is often whichever is most dramatic. Different strains have radically different fatality rates, and a 50 percent mortality claim is true for one variant but wildly misleading for another. Knowing which number applies to which situation is the difference between informed concern and unnecessary panic.
The case fatality rate range by strain
Hantavirus case fatality rates published in medical literature span a 50-fold range. The variation is real and reflects genuine biological differences between strains, geographic differences in care availability, and methodological differences in how studies count cases. The strains break into three rough tiers.
Tier 1: High mortality (30-50%)
Andes virus in Argentina, Chile, and Uruguay: 30-50 percent case fatality in published series. The 2018-2019 Epuyén cluster had approximately 35 percent mortality among confirmed cases. Recent improvements in ICU care have brought the lower end of this range toward 25-30 percent in well-resourced settings.
Araraquara virus in Brazil: approximately 50 percent case fatality, comparable to Andes but without person-to-person transmission documented.
Sin Nombre virus in the United States and Canada: approximately 38 percent case fatality based on CDC surveillance data over multiple decades. This is the strain that killed Betsy Arakawa in February 2025.
Tier 2: Moderate mortality (5-15%)
Hantaan virus in Korea, China, and Russia: 5-15 percent case fatality for severe HFRS. Mortality has declined substantially over recent decades due to improved supportive care, particularly hemodialysis availability for kidney failure.
Dobrava-Belgrade virus in the Balkans and Eastern Europe: 5-15 percent case fatality, similar to Hantaan. This is the most severe European hantavirus.
Choclo virus in Panama: approximately 10 percent case fatality. Disease tends to be less severe than other New World strains.
Tier 3: Low mortality (under 1%)
Puumala virus in Northern Europe and Russia: less than 1 percent case fatality. Causes a milder form of HFRS sometimes called nephropathia epidemica. Finland reports 1,000-3,000 cases annually with very few deaths.
Seoul virus globally: approximately 1 percent case fatality. Symptoms are typically mild and most patients recover fully without specific treatment.
Why the same disease has such different outcomes
The strain-level variation has three biological drivers and two epidemiological drivers.
Biological factor 1: Organ tropism
New World hantaviruses (Sin Nombre, Andes, Araraquara, Choclo) primarily attack the pulmonary vasculature, causing fluid leakage into the lungs that produces non-cardiogenic pulmonary edema. Without effective ventilation support, this is rapidly fatal. Old World hantaviruses (Hantaan, Puumala, Seoul, Dobrava) primarily attack the renal vasculature, causing kidney failure that is more manageable with available medical technology (dialysis).
This is the single biggest reason why Americas hantaviruses kill at much higher rates than Eurasian ones. Lung failure is harder to manage than kidney failure with current medical technology.
Biological factor 2: Vascular leak severity
Within New World strains, the severity of vascular endothelial damage varies. Sin Nombre and Andes cause more severe and rapid vascular leak than Choclo. The leakier the vessels, the faster fluid accumulates in critical organs, and the narrower the window for intervention.
Biological factor 3: Viral replication kinetics
Some strains reach higher peak viral loads in tissue than others. Higher viral loads mean more vascular cells damaged at once, more inflammatory cytokine release, and more severe systemic illness. Andes virus reaches particularly high viral loads, which correlates with its high mortality and its uniqueness in being human-to-human transmissible.
Epidemiological factor 1: Care access
Hantavirus has no antiviral cure. Survival depends almost entirely on supportive care quality. The difference between a Sin Nombre case treated in an academic medical center with ECMO availability versus one treated in a rural community hospital without advanced respiratory support is enormous. Published case series from the US show mortality dropping from 50 percent to under 20 percent at hospitals with ECMO capability.
This is one reason mortality rates have declined over time even for strains where biological factors haven't changed. Care has improved.
Epidemiological factor 2: Diagnosis timing
Early recognition of hantavirus allows for proactive management of fluid balance, early transfer to ECMO-capable facilities, and avoidance of harmful interventions like over-aggressive fluid resuscitation or corticosteroids. Late diagnosis often means patients have already received counterproductive treatment based on a wrong working diagnosis.
This is why physician education about hantavirus and patient awareness of exposure history matter for outcomes. The 2025 Arakawa case, where hantavirus was suspected only after extensive workup, illustrates the diagnostic delay problem.
Which number applies to your situation
For most personal-risk decisions, the relevant mortality figure is the strain endemic to your location or recent travel.
If you live in the western United States, the relevant figure is the Sin Nombre virus mortality (~38%). If you live in Finland, the relevant figure is Puumala mortality (under 1%). These two numbers are both real and both refer to "hantavirus" but describe very different diseases.
For the 2026 MV Hondius cluster, the relevant figure is Andes virus mortality, which has historically been 30-50% but has dropped toward 20-25% in cases receiving advanced ICU care. The actual outbreak case fatality rate so far (3 deaths among 6-8 confirmed/suspected cases) is consistent with these ranges.
Why the 50% number gets used a lot
Journalism often cites 50 percent as the hantavirus mortality rate. This is technically true for Andes virus and Araraquara in untreated or undertreated cases, but it is misleading when applied generally. The 50% figure represents the worst-case scenario for the most dangerous strain with limited care access.
The pattern repeats with other rare diseases. Ebola mortality is often quoted as 90% (the original 1976 outbreak) or 50% (more typical) when actual modern outbreaks with care access have ranged 40-65%. The dramatic numbers come from the worst situations and the worst-prepared responses.
For hantavirus specifically, a more honest summary would be: "Hantavirus mortality varies widely by strain. For Andes virus and Sin Nombre in well-resourced settings, current mortality is roughly 20-35%. For Puumala virus, mortality is under 1%."
The ECMO effect
Extracorporeal membrane oxygenation has had a transformational effect on New World hantavirus survival. ECMO is a technique where blood is pumped through an external machine that adds oxygen and removes carbon dioxide, allowing the lungs to rest while severe vascular leak heals.
Pre-ECMO era data on Sin Nombre virus showed mortality near 50 percent. Modern data from ECMO-capable centers shows mortality around 20 percent for severe HPS cases that receive ECMO. The catch is that ECMO requires highly resourced ICU teams, specialized equipment, and the ability to transport unstable patients to capable centers.
This creates a stark geographic mortality disparity. Patients with severe hantavirus in remote rural areas have worse outcomes than patients with the same disease in metropolitan academic medical centers. The biological pathology is identical; the survival difference is purely about care infrastructure.
Trend over time
Hantavirus mortality has decreased over recent decades for most strains, though the absolute numbers remain sobering. The improvement comes from several sources:
- Better understanding of the disease's distinctive features (avoiding fluid overload, recognizing pulmonary edema as non-cardiogenic).
- ECMO availability expansion in tertiary care centers.
- Earlier diagnosis through better physician awareness in endemic regions.
- Improved supportive care protocols for the cardiopulmonary phase.
The trend is gradual and dependent on healthcare system development. Where ECMO capacity remains limited, mortality has improved less.
What this means for outbreak monitoring
For someone tracking hantavirus outbreaks, the mortality rate provides context for the severity of the event but should not be misinterpreted as predicting your personal risk if you are not actually exposed.
A 50 percent fatality rate in a 6-case outbreak means 3 deaths total, which is awful for the affected families and important from a public health perspective, but does not translate into mass-casualty risk for the general public. A 30 percent fatality rate among hospitalized cases also tells you nothing about the fatality rate among all infected people, since many infections are mild or asymptomatic and never enter hospital statistics.
The most useful framing of hantavirus mortality is: it is a severe disease for the unlucky few who develop full HPS or severe HFRS, with current survival depending heavily on early recognition and access to advanced care. The disease is not a pandemic threat, the mortality rates do not generalize to the population, and the right response to an outbreak is informed vigilance rather than fear.